Some medical technologies that use artificial intelligence might benefit patients but result in a drop in health system revenues. This could make widespread adoption of AI in medicine a tough sell.
Healthcare is a world of perverse incentives. One person’s waste is another person’s annual bonus. If you have shares in Novo Nordisk, you don’t really want people to eat more fruits and vegetables, because then sales of diabetes meds might drop. The same is true on a larger scale for hospital systems that get paid to conduct tests and perform surgeries instead of keeping people healthy.
It doesn’t pay—yet—to keep people healthy. Many entrepreneurs and government leaders are dragging the American healthcare system away from the fee-for-service model, but the road to pay for performance medical care is long and winding.
HeartFlow is the perfect example of how a positive change for patients could mean a drop in health system revenues. The company’s goal is to improve care for heart disease by avoiding both under- and over-treatment. HeartFlow takes data from a CT scan and turns it into a 3D model of the veins and arteries that supply blood to the heart.
“If our system is adopted, the net annual savings would be $2 billion for one commercial payer,” said John Stevens, MD and president of HeartFlow. “We could avoid 250,000 unnecessary procedures and even save 30,000 lives.” Stevens shared these shocking numbers at HLTH 2018 in early May in Las Vegas.
Image Credit: From article
News This Week
Largest-Ever Physics Survey Raises New Doubts About Our Model of the Universe
Physicists around the world remain deeply divided on key mysteries of the universe, from dark matter to quantum gravity. The standard cosmological model failed to gain majority support, and no leading theory dominated the [...]
Scientists Just Overturned a 100-Year-Old Belief About Bacteria in the Lungs
New findings raise questions about the role of microbes living in the lungs. More than 35 trillion bacteria live throughout the human body, forming microbiomes in the gut, mouth, lungs, skin, and urogenital tract. [...]
GHCE Concept
From the preface of the book Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artificial Intelligence, Edited by Frank Boehm: Since the publication of my first book (Nanomedical Device and Systems [...]
Novartis, Ionis drug failure spurs questions
Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a result with important implications for cardiovascular drug research. Dive Brief: An RNA drug from [...]
New injectable treatment helps the brain rebuild after stroke
Biomedical engineers at Duke University have created an injectable biomaterial that may help the brain recover from damage left behind by an ischemic stroke. In experiments with mice, the material transformed the cavity created [...]
Scientists Discover a Hidden “Immune Organ” Inside the Skull
Researchers discovered lymph node-like immune hubs inside skull bone marrow that appear to act as rapid-response centers for the brain. For decades, the brain was thought to operate largely apart from the immune system. [...]
Engineered tRNAs and lipid nanoparticles target nonsense mutation cystic fibrosis
Researchers have developed a potential new approach for treating a form of cystic fibrosis caused by so-called nonsense mutations, combining chemically modified transfer RNAs with lipid nanoparticles designed to deliver the therapy directly to [...]
New pancreatic cancer drug carries a $39,800 monthly list price
A groundbreaking treatment for one of the most common forms of pancreatic cancer has been approved in pill form by the FDA. Revolution Medicines’ oral tablet daraxonrasib, branded as Rasonque, reduced the risk of [...]
Leave A Comment